The relationship between comedo-DCIS and basal-like breast cancer illustrates this point, and suggests that p63/Her2/neu expressions may be used as markers for identifying breast cancers that may progress to a novel clinical subgroup of basal-like breast cancer. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.